POLISCOPE
Back to bills

The civic record

Read. Follow. Verify.
High Impact

Office of National Drug Control Policy Reauthorization Act of 2024

Record date · December 9, 2024

Introduced
Committee
Floor Vote
Passed
Law

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

What This Bill Would Do

This bill reauthorizes the Office of National Drug Control Policy through 2031 and expands its mandate to include , fentanyl interdiction, and data-driven reporting on drug trafficking. It increases funding for various anti-drug programs and requires new strategies for addressing opioid overdoses and border-related drug threats.

Why it matters

The bill sets federal priorities and funding levels for drug control and addiction treatment programs through 2031, directly impacting the resources available to state and local law enforcement and public health agencies for opioid overdose prevention and fentanyl interdiction.

Who It Would Affect

Groups the bill's text would affect if enacted, as described in the record. Being affected is not a position for or against it.

Directly affected

State and local law enforcement

These agencies will receive federal guidance and potential funding adjustments for drug trafficking enforcement and fentanyl interdiction.

Directly affected

Public health agencies

These entities are tasked with implementing new strategies for the distribution and education of opioid overdose reversal medications.

Directly affected

Assistant United States Attorneys

These individuals may be subject to temporary reassignment to prioritize the investigation and prosecution of fentanyl trafficking organizations.

Key Facts

You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.

Frequently Asked Questions

What is the primary goal of this bill?
The bill aims to reauthorize the Office of National Drug Control Policy and update its strategies to focus more heavily on fentanyl interdiction, , and the use of evidence-based data to combat drug trafficking.
Does this bill change how opioid reversal drugs like naloxone are handled?
Yes, it mandates that the Office of National Drug Control Policy prioritize the availability of opioid antagonists and requires a new federal strategy to ensure these medications are accessible to first responders and the public.
How does this bill affect law enforcement resources?
It provides specific funding for fentanyl interdiction and allows the Attorney General to temporarily reassign federal prosecutors to focus on fentanyl-related cases.

What else do you want to know?

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Where This Stands

Currently filed. The next step in the legislative lifecycle is Committee.

Version history

Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.

View official text →

Full breakdown

Who this bill affects and the strongest case for and against it, written only from the bill’s own text.

Discoveries

1 pattern noticed across the record

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift90% confidence

Increased Focus on Fentanyl

The bill marks a significant shift toward prioritizing fentanyl-specific interdiction, including dedicated funding and prosecutorial resources.

Connected Entities

Nadler, Plaskett, Gonzalez-Colon and 8 more
PersonNadler“Representative sponsoring the bill”Map →
PersonPlaskett“Representative sponsoring the bill”Map →
PersonGonzalez-Colon“Representative sponsoring the bill”Map →
OrganizationCommittee on Oversight and Accountability“Committee responsible for reviewing the bill”Map →
PersonComer“Representative introducing the bill”Map →
PersonDuarte“Representative sponsoring the bill”Map →
OrganizationHouse Energy and Commerce Committee“Committee responsible for reviewing the bill”Map →
OrganizationCommittee on the Judiciary“Committee responsible for reviewing the bill”Map →
PersonRaskin“Representative sponsoring the bill”Map →
OrganizationOffice of National Drug Control Policy“The agency being reauthorized”Map →
OrganizationU.S. Government Publishing Office“Source of the document”Map →

Sources

Open source document

www.congress.gov

Analysis Score

0–100
  • Significance85
    How much this matters to a regular citizen
  • Controversy40
    Intensity of disagreement among stakeholders
  • Entertainment10
    Compellingness for a non-policy-wonk reader
  • Buzz30
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record